From Pulse 2.0 · Amit Chowdhry · · 1m
UCB Raises 2026 Revenue Growth Guidance
UCB updates 2026 revenue and EBITDA growth forecasts after strong BIMZELX and CIMZIA performance.
In brief
UCB updates 2026 revenue and EBITDA growth forecasts after strong BIMZELX and CIMZIA performance. UCB raised 2026 revenue growth to low-20% range and adjusted EBITDA growth to low-to-mid-40% range due to BIMZELX and CIMZIA commercial success. Originally reported by Pulse 2.0.
UCB Updates 2026 Financial Guidance
UCB raised full-year 2026 revenue growth guidance to low-20% range at constant exchange rates.
Adjusted EBITDA Growth Forecast Increased
UCB now expects adjusted ebitda growth in low-to-mid-40% range at constant exchange rates.
BIMZELX Commercial Momentum
BIMZELX gains commercial traction in the united states with stronger prescription volumes and patient retention.
CIMZIA Sustained Market Performance
CIMZIA maintains volume growth despite contraction in the broader anti-tnf treatment market.
Improved Pricing Dynamics
BIMZELX shows more favorable net pricing dynamics in the united states with higher average revenue per patient.
2027 Financial Results Timeline
UCB will publish full-year 2026 financial results and 2027 guidance on february 25, 2027.
What to remember
UCB raised 2026 revenue growth to low-20% range and adjusted EBITDA growth to low-to-mid-40% range due to BIMZELX and CIMZIA commercial success.
